Viemed Healthcare (VMD) reported $270M in revenue for fiscal 2025, +20.5% year on year. That ranks #2538 by revenue among 2853 SEC filers and #257 in Healthcare. Net income was $15.4M, a net margin of 5.7%. Revenue has grown 22.7% a year on average since 2018 ($64.5M then). The fiscal 2025 balance sheet shows $199M in total assets, $13.5M in cash and $11.3M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $270M | +20.5% | FY20252025-12-31 |
| Gross profitGrossProfit | $155M | +16.7% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $22.9M | +28.2% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $15.4M | +35.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $51.9M | +32.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $40.0M | +5.9% | FY20252025-12-31 |
| Total assetsAssets | $199M | +12.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $142M | +7.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $13.5M | −23.0% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $11.3M | +214.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $75.4M | $2.6M | Open → |
| Q2 20262026-06-30 | $78.1M | $2.8M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Viemed Healthcare, Inc.
- Ticker
- VMD
- Exchange
- Nasdaq
- SIC classification
- Services-Misc Health & Allied Services, NEC (8090)
- Fiscal year end
- 12-31
- CIK
- 0001729149
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KMar 4, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Adaptive BiotechnologiesADPT | $277M | −$59.5M |
| VericelVCEL | $276M | $16.5M |
| HarrowHROW | $272M | −$5.1M |
| Viemed HealthcareVMD | $270M | $15.4M |
| Vireo GrowthVREOF | $269M | −$68.1M |
| Ligand PharmaceuticalsLGND | $268M | $124M |
| Iovance BiotherapeuticsIOVA | $264M | −$391M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Viemed Healthcare — Key figures |url=https://companiesranked.com/en/company/viemed-healthcare |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Viemed Healthcare — Key figures. CompaniesRanked. https://companiesranked.com/en/company/viemed-healthcareBibTeX
@misc{companiesranked-en-company-viemed-healthcare-2026,
author = {{CompaniesRanked}},
title = {{Viemed Healthcare — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/viemed-healthcare}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001729149-26-000009 · March 4, 2026
{{cite web |title=Viemed Healthcare — Key figures — 10-K (0001729149-26-000009) |url=https://www.sec.gov/Archives/edgar/data/1729149/000172914926000009/vmd-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-04}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.